Phosphate binder pill burden and cardiovascular events in patients undergoing hemodialysis

被引：0

作者：

Yoshida, Kiryu ^{[1
]}

Saito, Tomohiro ^{[2
]}

Kato, Tadashi ^{[2
]}

Takezaki, Toshiaki ^{[3
]}

Kato, Noriyuki ^{[3
]}

Mizobuchi, Masahide ^{[4
]}

Ogata, Hiroaki ^{[1
,5
]}

Koiwa, Fumihiko ^{[4
]}

Honda, Hirokazu ^{[2
]}

机构：

[1] Showa Univ, Dept Internal Med, Div Nephrol, Northern Yokohama Hosp, Chigasaki Chuo 35-1, Yokohama, Kanagawa 224850, Japan

[2] Showa Univ, Sch Med, Dept Med, Div Nephrol, Tokyo, Japan

[3] Saiyu Clin, Saitama, Japan

[4] Showa Univ, Fujigaoka Hosp, Dept Internal Med, Div Nephrol, Yokohama, Japan

[5] Showa Univ, Sch Med, Dept Med Educ, Tokyo, Japan

来源：

THERAPEUTIC APHERESIS AND DIALYSIS | 2025年 / 29卷 / 03期

关键词：

cardiovascular events; hemodialysis; phosphate binders; pill burden; CORONARY-ARTERY CALCIFICATION; MORTALITY RISK; DIALYSIS OUTCOMES; PRACTICE PATTERNS; SERUM PHOSPHORUS; CALCIUM; ASSOCIATION; PROGRESSION; MANAGEMENT; ADHERENCE;

D O I：

10.1111/1744-9987.70004

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background: Phosphate binders (PBs) are commonly prescribed to reduce serum phosphate levels. This study examined the association between the PB pill burden and cardiovascular events in hemodialysis patients. Methods: This retrospective cohort study included 395 patients undergoing hemodialysis between August 2018 and November 2023 at a single facility in Japan. Statistical analyses were conducted using baseline, time-averaged, and time-dependent Cox proportional hazard models. Results: Of the 395 included patients, cardiovascular events occurred in 121 patients (30.6%). The patients were categorized into tertiles based on their daily PB pill intake: T1 (<4 pills/day), T2 (4-8 pills/day), and T3 (>= 9 pills/day). T3 was associated with increased cardiovascular risk (vs. T1 hazard ratio [HR] = 1.51, p = 0.064; vs. T2 HR = 2.06, p = 0.005). Similar results were obtained for the time-averaged and time-dependent models. Conclusion: A high PB pill burden (>= 9/day) is associated with increased cardiovascular risk in patients undergoing hemodialysis.

引用

页码：333 / 344

页数：12

共 29 条

[1] Effect of Tenapanor on Phosphate Binder Pill Burden in Hemodialysis Patients [J].

Akizawa, Tadao ;

Sato, Yu ;

Ikejiri, Kazuaki ;

Kanda, Hironori ;

Fukagawa, Masafumi .

KIDNEY INTERNATIONAL REPORTS, 2021, 6 (09) :2371-2380

[2] Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study [J].

Block, GA ;

Hulbert-Shearon, TE ;

Levin, NW ;

Port, FK .

AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 31 (04) :607-617

[3] Use of phosphate-binding agents is associated with a lower risk of mortality [J].

Cannata-Andia, Jorge B. ;

Fernandez-Martin, Jose L. ;

Locatelli, Francesco ;

London, Gerard ;

Gorriz, Jose L. ;

Floege, Juergen ;

Ketteler, Markus ;

Ferreira, Anibal ;

Covic, Adrian ;

Rutkowski, Boleslaw ;

Memmos, Dimitrios ;

Bos, Willem-Jan ;

Teplan, Vladimir ;

Nagy, Judit ;

Tielemans, Christian ;

Verbeelen, Dierik ;

Goldsmith, David ;

Kramar, Reinhard ;

Martin, Pierre-Yves ;

Wuethrich, Rudolf P. ;

Pavlovic, Drasko ;

Benedik, Miha ;

Emilio Sanchez, Jose ;

Martinez-Camblor, Pablo ;

Naves-Diaz, Manuel ;

Carrero, Juan J. ;

Zoccali, Carmine .

KIDNEY INTERNATIONAL, 2013, 84 (05) :998-1008

[4] Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients [J].

Chertow, GM ;

Burke, SK ;

Raggi, P .

KIDNEY INTERNATIONAL, 2002, 62 (01) :245-252

[5] Pill Burden, Adherence, Hyperphosphatemia, and Quality of Life in Maintenance Dialysis Patients [J].

Chiu, Yi-Wen ;

Teitelbaum, Isaac ;

Misra, Madhukar ;

de Leon, Essel Marie ;

Adzize, Tochi ;

Mehrotra, Rajnish .

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 4 (06) :1089-1096

[6] Phosphate binder pill burden, patient-reported non-adherence, and mineral bone disorder markers: Findings from the DOPPS [J].

Fissell, Rachel B. ;

Karaboyas, Angelo ;

Bieber, Brian A. ;

Sen, Ananda ;

Li, Yun ;

Lopes, Antonio A. ;

Akiba, Takashi ;

Bommer, Juergen ;

Ethier, Jean ;

Jadoul, Michel ;

Pisoni, Ronald L. ;

Robinson, Bruce M. ;

Tentori, Francesca .

HEMODIALYSIS INTERNATIONAL, 2016, 20 (01) :38-49

[7] Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population [J].

Floege, Juergen ;

Kim, Joseph ;

Ireland, Elizabeth ;

Chazot, Charles ;

Drueke, Tilman ;

de Francisco, Angel ;

Kronenberg, Florian ;

Marcelli, Daniele ;

Passlick-Deetjen, Jutta ;

Schernthaner, Guntram ;

Fouqueray, Bruno ;

Wheeler, David C. .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 2011, 26 (06) :1948-1955

[8] Clinical Practice Guideline for the Management of Chronic Kidney Disease-Mineral and Bone Disorder [J].

Fukagawa, Masafumi ;

Yokoyama, Keitaro ;

Koiwa, Fumihiko ;

Taniguchi, Masatomo ;

Shoji, Tetsuo ;

Kazama, Junichiro James ;

Komaba, Hirotaka ;

Ando, Ryoichi ;

Kakuta, Takatoshi ;

Fujii, Hideki ;

Nakayama, Msasaaki ;

Shibagaki, Yugo ;

Fukumoto, Seiji ;

Fujii, Naohiko ;

Hattori, Motoshi ;

Ashida, Akira ;

Iseki, Kunitoshi ;

Shigematsu, Takashi ;

Tsukamoto, Yusuke ;

Tsubakihara, Yoshiharu ;

Tomo, Tadashi ;

Hirakata, Hideki ;

Akizawa, Tadao .

THERAPEUTIC APHERESIS AND DIALYSIS, 2013, 17 (03) :247-288

[9]

Ganesh SK, 2001, J AM SOC NEPHROL, V12, P2131, DOI 10.1681/ASN.V12102131

[10] Optimal Phosphate Control Related to Coronary Artery Calcification in Dialysis Patients [J].

Isaka, Yoshitaka ;

Hamano, Takayuki ;

Fujii, Hideki ;

Tsujimoto, Yoshihiro ;

Koiwa, Fumihiko ;

Sakaguchi, Yusuke ;

Tanaka, Ryoichi ;

Tomiyama, Noriyuki ;

Tatsugami, Fuminari ;

Teramukai, Satoshi .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (03) :723-735

← 1 2 3 →